Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary) ; RG 6146 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.
- 14 May 2019 Planned End Date changed from 29 May 2021 to 25 Sep 2019.
- 14 May 2019 Planned primary completion date changed from 29 May 2021 to 25 Sep 2019.